

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

May 2019

Vol. 47, No. 5

CONTENTS

ARTICLES

- § Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. *Jean-Philippe Émond, Adrien Labriet, Sylvie Desjardins, Michèle Rouleau, Lyne Villeneuve, Hélène Hovington, Hervé Brisson, Louis Lacombe, David Simonyan, Patrick Caron, Martine Périgny, Bernard Tétu, John K. Fallon, Kathrin Klein, Philip C. Smith, Ulrich M. Zanger, Chantal Guillemette, and Eric Lévesque* **444**
- § Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. *Ronald de Vries, Frank Jacobs, Geert Mannens, Jan Snoeys, Filip Cuyckens, Caly Chien, and Peter Ward* **453**
- In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites. *Yuli Qian, Xinwen Wang, and John S. Markowitz* **465**
- § Time Course of Aldehyde Oxidase and Why It Is Nonlinear. *Armina Abbasi, Erickson M. Paragas, Carolyn A. Joswig-Jones, John T. Rodgers, and Jeffrey P. Jones* **473**
- A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes. *Keith A. Riccardi, David A. Tess, Jian Lin, Roshan Patel, Sangwoo Ryu, Karen Atkinson, Li Di, and Rui Li* **484**
- § Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. *Emi Kimoto, Manoli Vourvahis, Renato J. Scialis, Heather Eng, A. David Rodrigues, and Manthena V. S. Varma* **493**
- § Supplemental material is available online at <http://dmd.aspetjournals.org>.

- § Oxidative Deamination of Emixustat by Human Vascular Adhesion Protein-1/Semicarbazide-Sensitive Amine Oxidase. *Michael J. Reid, Russell Eyre, and Terry Podoll* **504**
- Role of ABCG2 in Secretion into Milk of the Anti-Inflammatory Flunixin and Its Main Metabolite: In Vitro-In Vivo Correlation in Mice and Cows. *Dafne Garcia-Mateos, Alba Maria Garcia-Lino, Indira Alvarez-Fernandez, Esther Blanco-Paniagua, Alvaro de la Fuente, Ana Isabel Alvarez, and Gracia Merino* **516**
- § Characterization of Fasiglifam-Related Liver Toxicity in Dogs. *Akifumi Kogame, Yuu Moriya, Ikuo Mori, Liping Pan, Akio Morohashi, Takuya Ebihara, Hideo Fukui, Yoshihiko Tagawa, and Leslie Z. Benet* **525**
- § Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors. *Stephanie N. Liu, Jessica Bo Li Lu, Christy J. W. Watson, Philip Lazarus, Zeruesenay Desta, and Brandon T. Gufford* **535**
- § A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity. *Shuai Wang, Buyun Chen, Peter Dragovich, Thomas Pillow, Leanna Staben, Jun Guo, Dian Su, Chenghong Zhang, Sudheer Bobba, Yong Ma, Jianshuang Wang, Dewakar Sangaraju, BinQing Wei, Gail Lewis Phillips, Cyrus Khojasteh, and Donglu Zhang* **547**

ERRATUM

Correction to “Gas-Phase Rearrangement of the O-Glucuronide of Vildagliptin Forms Product-Ion Fragments Suggesting Wrongly an *N*-Glucuronide” **545**

About the cover: A schematic of MVC disposition and DDI mechanisms is illustrated. See the article by Kimoto et al., (dx.doi.org/10.1124/dmd.118.085241).